Blood-Based Cancer Diagnostic Stock Surges 1 Trillion Won in One Day

Guardant Health Inc. (NASDAQ: GH) closed at $97 on the U.S. stock market, up 5.15%, lifting its market capitalization to approximately $12.7 billion (about KRW 18 trillion). The one-day gain added roughly $690 million (nearly KRW 1 trillion) to its market value, with 1.72 million shares traded.

Recently, Guardant Health announced a multi-year collaboration with precision oncology company Nuvalent to leverage its Infinity liquid biopsy platform for new drug development and companion diagnostics, and reached a settlement with Foundation Medicine in their digital sequencing patent dispute. At the same time, the company is undergoing an executive transition as Chief Medical Officer Craig Eagle has announced his resignation effective May 8.

Headquartered in California, Guardant Health is a precision oncology diagnostics firm offering services such as the blood-based liquid biopsy test Guardant360 and Shield, an early colorectal cancer detection assay.